| Symbol | LENZ |
|---|---|
| Name | LENZ THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 201 HASKINS WAY,SUITE 210, SOUTH SAN FRANCISCO, California, 94080, United States |
| Telephone | +1 650 484-0886 |
| Fax | — |
| — | |
| Website | https://www.lenz-tx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001815776 |
| Description | LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. Additional info from NASDAQ: |
(30% Negative) LENZ THERAPEUTICS, INC. (LENZ) Reports Q3 2026 Financial Results
Read moreLENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Read moreLENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026
Read moreLENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
Read more(99% Neutral) LENZ THERAPEUTICS, INC. (LENZ) Announces New Board Appointment
Read moreNew Form SCHEDULE 13G - LENZ Therapeutics, Inc. <b>Filed:</b> 2026-06-26 <b>AccNo:</b> 0001104659-26-078313 <b>Size:</b> 15 KB
Read moreLENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand
Read moreRA CAPITAL MANAGEMENT, L.P. 🟢 acquired 22.1K shares (1 derivative) of LENZ Therapeutics, Inc. (LENZ) at $6.63 Transaction Date: Jun 15, 2026 | Filing ID: 000640
Read moreDirector George Jeffrey P. 🟢 acquired 22.1K shares (1 derivative) of LENZ Therapeutics, Inc. (LENZ) at $6.63 Transaction Date: Jun 15, 2026 | Filing ID: 000004
Read moreDirector Drapkin Kimberlee C 🟢 acquired 22.1K shares (1 derivative) of LENZ Therapeutics, Inc. (LENZ) at $6.63 Transaction Date: Jun 15, 2026 | Filing ID: 000001
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06270030 | Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solut… | Phase1 | Presbyopia | Completed | 2024-03-04 | 2024-04-10 | ClinicalTrials.gov |
| NCT06045299 | Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia | Phase3 | Presbyopia | Completed | 2023-09-27 | 2025-01-27 | ClinicalTrials.gov |
| NCT05936489 | Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in… | Phase1 | Eye Diseases | Completed | 2023-07-06 | 2023-10-03 | ClinicalTrials.gov |
| NCT05728944 | Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia | Phase3 | Presbyopia | Completed | 2023-03-06 | 2024-01-24 | ClinicalTrials.gov |
| NCT05753189 | Phase 3 Safety Study of LNZ100 and LNZ101 for the Treatment of Presbyopia Subje… | Phase3 | Presbyopia | Completed | 2023-02-21 | 2024-02-09 | ClinicalTrials.gov |
| NCT05656027 | Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatm… | Phase3 | Presbyopia | Completed | 2022-12-19 | 2024-01-25 | ClinicalTrials.gov |
| NCT05431543 | Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidin… | Phase2 | Presbyopia | Completed | 2022-08-06 | 2022-12-14 | ClinicalTrials.gov |
| NCT05294328 | Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) a… | Phase2 | Presbyopia | Completed | 2022-05-05 | 2022-09-10 | ClinicalTrials.gov |
| NCT03201562 | A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100… | Phase2 | Presbyopia | Completed | 2017-04-30 | 2018-05-20 | ClinicalTrials.gov |
| NCT02554396 | Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to M… | Phase2 | Presbyopia | Completed | 2015-09-01 | 2015-11-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Brimonidine | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Vehicle | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Brimonidine | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Vehicle | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Vehicle | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Brimonidine | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Vehicle | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Brimonidine | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Vehicle | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Brimonidine | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Vehicle | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Brimonidine | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Placebo | Other | Phase PHASE2 | Presbyopia | COMPLETED | NCT02554396 |
| PRX-100 | Other | Phase PHASE2 | Presbyopia | COMPLETED | NCT02554396 |
| Vehicle | Other | Phase PHASE2 | Presbyopia | COMPLETED | NCT03201562 |
| Aceclidine | Other | Phase PHASE2 | Presbyopia | COMPLETED | NCT03201562 |
| Aceclidine+tropicamide combination | Other | Phase PHASE2 | Presbyopia | COMPLETED | NCT03201562 |
| Aceclidine | Other | Phase PHASE1 | Eye Diseases | COMPLETED | NCT05936489 |
| Aceclidine + Brimonidine | Other | Phase PHASE1 | Eye Diseases | COMPLETED | NCT05936489 |
| Placebo (Vehicle) ophthalmic solution | Other | Phase PHASE1 | Presbyopia | COMPLETED | NCT06270030 |
| LNZ100 (Aceclidine) ophthalmic solution | Other | Phase PHASE1 | Presbyopia | COMPLETED | NCT06270030 |
| LNZ101 (Aceclidine /Brimonidine) ophthalmic solution | Other | Phase PHASE1 | Presbyopia | COMPLETED | NCT06270030 |
| Vehicle proprietary ophthalmic solution | Other | Phase PHASE2 | Presbyopia | COMPLETED | NCT05431543 |
| Aceclidine ophthalmic solution | Other | Phase PHASE2 | Presbyopia | COMPLETED | NCT05431543 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE2 | Presbyopia | COMPLETED | NCT05431543 |
| Vehicle Proprietary Ophthalmic Solution | Other | Phase PHASE2 | Presbyopia | COMPLETED | NCT05294328 |
| Aceclidine ophthalmic solution | Other | Phase PHASE2 | Presbyopia | COMPLETED | NCT05294328 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE2 | Presbyopia | COMPLETED | NCT05294328 |
| Aceclidine Ophthalmic Solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Placebo | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Placebo (Vehicle) ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT06045299 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT06045299 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT06045299 |
| Vehicle | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05728944 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05728944 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05728944 |
| Brimonidine | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| LNZ100 (Aceclidine) ophthalmic solution | DRUG | Phase PHASE1 | Presbyopia | COMPLETED | NCT06270030 |
| LNZ101 (Aceclidine /Brimonidine) ophthalmic solution | DRUG | Phase PHASE1 | Presbyopia | COMPLETED | NCT06270030 |
| Placebo (Vehicle) ophthalmic solution | DRUG | Phase PHASE1 | Presbyopia | COMPLETED | NCT06270030 |
| Aceclidine + Brimonidine | DRUG | Phase PHASE1 | Eye Diseases | COMPLETED | NCT05936489 |
| Aceclidine Ophthalmic Solution | DRUG | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Brimonidine | DRUG | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Vehicle proprietary ophthalmic solution | DRUG | Phase PHASE2 | Presbyopia | COMPLETED | NCT05431543 |
| Vehicle Proprietary Ophthalmic Solution | DRUG | Phase PHASE2 | Presbyopia | COMPLETED | NCT05294328 |
| Aceclidine ophthalmic solution | DRUG | Phase PHASE3 | Presbyopia | COMPLETED | NCT06045299 |
| Aceclidine+Brimonidine combination ophthalmic solution | DRUG | Phase PHASE3 | Presbyopia | COMPLETED | NCT06045299 |
| Vehicle | DRUG | Phase PHASE3 | Presbyopia | COMPLETED | NCT05728944 |
| Aceclidine | DRUG | Phase PHASE1 | Eye Diseases | COMPLETED | NCT05936489 |
| Aceclidine+tropicamide combination | DRUG | Phase PHASE2 | Presbyopia | COMPLETED | NCT03201562 |
| Placebo | DRUG | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| PRX-100 | DRUG | Phase PHASE2 | Presbyopia | COMPLETED | NCT02554396 |